The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Biotech BeiGene has announced that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to January 20, 2023 for the supplementary new drug application (sNDA) submitted for Brukinsa as a treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 14 June 2022
RNAi therapeutics company Alnylam Pharmaceuticals today announced that the US Food and Drug Administration (FDA) approved Amvuttra (vutrisiran), an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 14 June 2022
A major early-stage win in large B-cell lymphoma (LBCL) will take some pressure off the architects of AbbVie’s $750 million bet on Danish biotech Genmab. 14 June 2022
Danish vaccine developer Bavarian Nordic today announced that the European Health Emergency Preparedness and Response Authority (HERA) has ordered 110,000 doses of MVA-BN smallpox/monkeypox vaccine, which will be made available to European Union member states, Norway and Iceland in response to the current monkeypox outbreak. 14 June 2022
Shares of Valneva on Monday dropped by as much as 28%, after the specialty vaccine maker warned over prospects for its COVID-19 vaccine, VLA2001. 14 June 2022
German biotech Evotec today revealed it as entered a drug discovery collaboration with Janssen Pharmaceutica, a part of US healthcare giant Johnson & Johnson. 14 June 2022
Amylyx Pharmaceuticals’ shares closed down 3.9% at $13.00 on Monday, despite announcing it has received the first regulatory approval for its Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), from Health Canada, for the treatment of amyotrophic lateral sclerosis (ALS). 14 June 2022
French biotech ImCheck Therapeutics today announced the closing of a 96 million-euro ($103 million) financing, co-led by Earlybird and Andera Partners. 13 June 2022
Colorado-based data-driven proteomics technology company SomaLogic has signed a licensing agreement with precision oncology firm OncoHost. 13 June 2022
Massachusetts, USA-based biotech Selecta Biosciences, which is leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced several pipeline advancements and partnership updates. 13 June 2022
There are hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies. 13 June 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics announced today it has appointed industry veteran David Gilman to the new role of chief business and strategy officer, reporting to chief executive Ameet Mallik effective July 1. 13 June 2022
Even as Germany’s Boehringer Ingelheim has obtained ad-interim injunctions against four Indian pharma companies that launched generic versions of the multinational's patent-protected drug linagliptin, Indian generic major Natco said that US firms Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit against it on two old patents associated with its glatiramer acetate injection. 13 June 2022
Vertex Pharmaceuticals and CRISPR Therapeutics have presented new data on exa-cel at the European Hematology Association (EHA) annual meeting. 13 June 2022
The pandemic-induced bounty reaped by vaccine leaders Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) may have passed, but two traditional players have not abandoned hope of making a contribution. 13 June 2022
Novo Nordisk has announced results of once-weekly Sogroya (somapacitan) injection in helping children achieve growth targets of annualized height velocity (AHV), strengthening the Danish company’s reach beyond its core lead in diabetes care. 13 June 2022
Swiss pharma giant Novartis on Sunday announced long-term five-year follow-up results from the ELIANA pivotal clinical trial of Kymriah (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). 13 June 2022
Over the past few years, CAR T-cell therapies have also become transformative treatment options for patients with many forms of blood cancers, such as lymphoma and multiple myeloma. The treatment method involves taking a patient's T cells, "re-engineering" them to kill cancer cells, and infusing them back into the patient. 13 June 2022